Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861- Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm, LIQ861- fixed dose arm
LIQ861 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: LIQ861 Dose Titration Arm | EXPERIMENTAL | - |
| Arm 2: LIQ861 Fixed Dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LIQ861 (treprostinil) inhalation powder - Dose Titration Arm | COMBINATION_PRODUCT | Treprostinil inhalation powder supplied as capsules in strengths of 26.5, 53, 79.5, and 106 mcg, administered by oral inhalation QID (approximately 3-4 hours apart during waking hours) for 21 days using the RS00 Model 8 Monodose DPI |
| LIQ861 (treprostinil) inhalation powder - fixed dose arm | COMBINATION_PRODUCT | Treprostinil inhalation powder supplied as 26.5 mcg capsules administered by oral inhalation QID (approximately 3-4 hours apart during waking hours) for 21 days using the RS00 Model 8 Monodose DPI |
Inclusion Criteria: * Male or female ≥18 years of age * Classification of SSc per the 2013 ACR/EULAR criteria. * Diagnosis or history of Raynaud's phenomenon * Minimum of 12 (maximum 100) symptomatic RP attacks documented in the ePRO diary over ≥4 separate days Exclusion Criteria: * ≥3 digital ul...
LIQ861 is being studied for the treatment of Raynaud's phenomenon secondary to systemic sclerosis in adults. The investigational therapy is intended for patients who experience symptomatic Raynaud's phenomenon attacks, which are episodes of reduced blood flow to the fingers and toes that occur as a complication of systemic sclerosis.
LIQ861 is being developed by Liquidia Corporation, which trades on the Nasdaq under the ticker symbol LQDA. The company is evaluating the therapy in adults with systemic sclerosis who have symptomatic Raynaud's phenomenon attacks.
LIQ861 is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 2 program is evaluating the drug in adults with Raynaud's phenomenon secondary to systemic sclerosis.
LIQ861 is being evaluated in a single Phase 2 trial, NCT07748000, titled A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks. The trial is not yet recruiting, is randomized and controlled, and plans to enroll 75 participants aged 18 years and older.
Yes. LIQ861 is an inhaled treprostinil powder, and the trial listing refers to it as LIQ861 (treprostinil) inhalation powder. The study includes a dose titration arm and a fixed dose arm, which appear in alternative names for the asset such as LIQ861 dose titration arm and LIQ861 fixed dose arm.
The Phase 2 study NCT07748000 is a randomized, controlled trial of LIQ861 in adults with systemic sclerosis who have symptomatic Raynaud's phenomenon attacks. It is not double blinded, is not biomarker selected, does not enroll healthy volunteers, and plans to enroll 75 participants of any sex aged 18 years and older.